Voyager Therapeutics (VYGR) – Company Press Releases
-
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
-
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
-
NorthStar Appoints Peter Pfreundschuh to Board of Managers
-
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
-
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
-
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
-
Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast
-
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research
-
Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference
-
Voyager Therapeutics Announces Pricing of Public Offering
-
Voyager Therapeutics Announces Proposed Public Offering
-
Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
-
Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program
-
Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results
-
Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
-
Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference
-
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Voyager Therapeutics to Participate in Upcoming Investor Conferences
-
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer
-
Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results
-
Voyager Therapeutics to Present at the Canaccord Genuity Growth Conference
-
Voyager Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
-
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer
-
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
-
Voyager Therapeutics to Present at the Jefferies Healthcare Conference
-
Voyager Therapeutics Presents Robust, Multi-Species Results from Preclinical Studies of IV-Delivered, TRACER™-Generated Novel Capsids at the ASGCT 26th Annual Meeting
-
Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results
-
Voyager Therapeutics Announces Appointment of George Scangos, Ph.D., to Board of Directors
-
Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting
-
Voyager Therapeutics Announces First Quarter 2023 Conference Call and Webcast
-
Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer’s Disease and GBA1 Gene Therapy Program for Parkinson’s Disease at the AD/PD™ Conference
-
Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
-
Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets
-
Voyager Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
-
Voyager Therapeutics to Participate in Upcoming Investor Conferences
-
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurologic
-
Voyager Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors
-
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results
-
Voyager Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
-
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Voyager Therapeutics Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families
-
Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target
-
Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy
Back to VYGR Stock Lookup
